Amgen Buys Micromet for Anti-leukemia Drug Blinatumomab

Jan. 27, 2012
Price tag is $1.16 billion for German-American cancer research firm.

Biotech giant Amgen said Thursday it was buying the German-American cancer research firm Micromet, giving it access to Micromet's promising leukemia therapy.

Amgen said it would pay $1.16 billion for Micromet, founded by a team of German scientists to tap the potential of T-cell therapies to fight cancer.

The company, based in Rockville, Md., has developed blinatumomab, a T-cell based treatment for acute lymphoblastic leukemia and possibly non-Hodgkin's lymphoma that is still undergoing testing.

"Blinatumomab will serve as an important complement to our oncology pipeline and is representative of our corporate strategy, which is focused on developing and successfully commercializing therapeutics to treat patients with grievous illness," Amgen chief executive Kevin Sharer said in a statement.

Copyright Agence France-Presse, 2012

Popular Sponsored Recommendations

Service Lifecycle Management – Challenges and Opportunities

Feb. 18, 2024
Gain insights into the next wave of aftermarket optimization with Harvard Business Review’s whitepaper, in association with Tavant. Get an in-depth look at AI-powered Service ...

The Year of Results: Four Expectations for 2024 Manufacturing

Feb. 1, 2024
In 2024 manufacturers will need to focus on results, from achieving operational excellence to enhancing digital transformation, to navigating compliance. Stay ahead with crucial...

Navigating Disruption: A Leader’s Guide to Strategy Under Uncertainty

Nov. 1, 2023
AI, sustainability, digital--industrials are facing disruptive forces that are redefining what it takes to win. What got your company where it is today won’t get you where you...

Top 3 Ways AI is Transforming Manufacturing Operations

Feb. 17, 2024
Unlock the power of Industry 4.0 with AI and IoT. Explore how real-time data and automation are reshaping manufacturing, driving efficiency and quality to new heights. Dive into...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!